September 7, 2017 / 4:33 PM / 3 months ago

BRIEF-Thrombogenics H1 operating loss flat at 15 million euros

Sept 7 (Reuters) - THROMBOGENICS NV:

* CASH POSITION - EUR 65.1 MILLION END H1 2017

* ‍THR-149 IS EXPECTED TO ENTER CLINIC IN H1 2018​

* ‍THR-687 IS EXPECTED TO ENTER CLINIC IN H1 2018​

* ‍FOR FIRST HALF OF 2017, THROMBOGENICS REPORTED A NET LOSS OF EUR 15.2 MILLION, OR EUR 0.42 PER SHARE​

* ‍EFFECTIVE 15 JUNE 2017, THROMBOGENICS’ LONG-TIME NON-EXECUTIVE DIRECTOR MR. THOMAS CLAY WAS APPOINTED CHAIRMAN OF BOARD OF DIRECTORS​

* H1 OPERATING LOSS EUR 15.0 MILLION VERSUS LOSS OF EUR 15.0 MILLION YEAR AGO

* IN H1 2017, CO GENERATED TOTAL REVENUES OF EUR 2.7 MILLION

* ‍WE ARE WELL POSITIONED TO DELIVER MULTIPLE MILESTONES OVER NEXT 12 MONTHS THAT COULD CREATE SIGNIFICANT VALUE FOR OUR SHAREHOLDERS​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below